Phase II Study of Esorubicin in the Treatment of Patients with Advanced Sarcoma
Authors:
- Giuseppe GiacconeGGGiuseppe Giaccone
- Michela DonadioMDMichela Donadio
- Alessandro CalciatiACAlessandro Calciati
- 1 January 1989
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 46 (5) , 285-287
Abstract
Esorubicin was administered to 12 patients with soft tissue sarcoma, 1 osteosarcoma and 1 desmoid tumor. Seven patients had never received chemotherapy before. Myelotoxicity was the main side effect, leukopenia being more pronounced than thrombocytopenia. No significant nonhematological toxicity occurred. Six patients had no change of median duration of 98 days and 7 patients progressed. The patient suffering from multiple-site lesions of a desmoid tumor obtained a long-lasting partial response. This study does not support further testing of esorubicin in sarcoma patients.Keywords
This publication has 8 references indexed in Scilit:
- 4′-deoxydoxorubicin, an inactive drug in small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- PHASE-I AND CLINICAL PHARMACOLOGICAL EVALUATION OF 4'-DEOXYDOXORUBICIN IN PATIENTS WITH ADVANCED CANCER1985
- Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma groupCancer, 1984
- Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin.Journal of Clinical Oncology, 1984
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984
- EFFECT OF 4'-DOXORUBICIN ANALOGS ON HETERO-TRANSPLANTATION OF HUMAN-TUMORS IN CONGENITALLY ATHYMIC MICE1981
- NEW DOXORUBICIN ANALOGS ACTIVE AGAINST DOXORUBICIN-RESISTANT COLON-TUMOR XENOGRAFTS IN THE NUDE-MOUSE1980
- Synthesis and antitumor activity of 4'-deoxydaunorubicin and 4'-deoxyadriamycinJournal of Medicinal Chemistry, 1976